Navigating BTK Inhibition and Second-Line Treatment in Mantle Cell Lymphoma: Updates From ASH 2025

Michael Wang, MD, and Nakhle Saba, MD, highlight current frontline treatment approaches for mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss factors that drive BTK inhibitor selection in second-line mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, detail phase 1/2 findings for sonrotoclax in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss data for the frontline combination of zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss the management of adverse effects associated with BTK inhibition in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss how ongoing research is shaping the evolving role of BTK and BCL2 inhibitors in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, highlight other key mantle cell lymphoma data presented at the 2025 ASH Annual Meeting and Exposition.

Michael Wang, MD, and Nakhle Saba, MD, discuss ongoing research to watch in mantle cell lymphoma.